These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 36136649)

  • 1. Clinical Course and Outcomes among COVID-19 Patients at the Hospitel in Bangkok: A Retrospective Study.
    Bruminhent J; Kaewsanga Y; Jiraaumpornpat W; Arnuntasupakul V; Suwatanapongched T; Kiertiburanakul S
    Trop Med Infect Dis; 2022 Sep; 7(9):. PubMed ID: 36136649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel.
    Surapat B; Kobpetchyok W; Kiertiburanakul S; Arnuntasupakul V
    Int J Clin Pract; 2022; 2022():3098527. PubMed ID: 35685498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand.
    Anugulruengkitt S; Teeraananchai S; Chantasrisawad N; Promsena P; Jantarabenjakul W; Puthanakit T
    IJID Reg; 2021 Dec; 1():159-162. PubMed ID: 35721777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study.
    Siripongboonsitti T; Tawinprai K; Cheirsilpa K; Ungtrakul T; Krisorakun W; Chotipanich C; Wimolsiri N; Noitun P; Srirattana N; Mahanonda N
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374302
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of Severity in Covid-19 Patients in Casablanca, Morocco.
    El Aidaoui K; Haoudar A; Khalis M; Kantri A; Ziati J; El Ghanmi A; Bennis G; El Yamani K; Dini N; El Kettani C
    Cureus; 2020 Sep; 12(9):e10716. PubMed ID: 33033687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mental health problems of asymptomatic or mildly symptomatic COVID-19 patients in hospitel in Thailand: A cross-sectional study.
    Kerdcharoen N; Kirdchok P; Wonglertwisawakorn C; Naviganuntana Y; Polruamngern N; Chinvararak C
    F1000Res; 2022; 11():1089. PubMed ID: 36726604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial.
    Chuah CH; Chow TS; Hor CP; Cheng JT; Ker HB; Lee HG; Lee KS; Nordin N; Ng TK; Zaid M; Zaidan NZ; Abdul Wahab S; Adnan NA; Nordin N; Tee TY; Ong SM; Chidambaram SK; Mustafa M;
    Clin Infect Dis; 2022 Aug; 75(1):e432-e439. PubMed ID: 34849615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand.
    Naorungroj T; Viarasilpa T; Tongyoo S; Detkaew A; Pinpak T; Wimolwattanaphan R; Ratanarat R; Promsin P; Thamrongpiroj P; Phumpichet A; Permpikul C
    Front Med (Lausanne); 2022; 9():1061955. PubMed ID: 36687414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial.
    Bosaeed M; Alharbi A; Mahmoud E; Alrehily S; Bahlaq M; Gaifer Z; Alturkistani H; Alhagan K; Alshahrani S; Tolbah A; Musattat A; Alanazi M; Jaha R; Sultana K; Alqahtani H; Al Aamer K; Jaser S; Alsaedy A; Ahmad A; Abalkhail M; AlJohani S; Al Jeraisy M; Almaziad S; Albaalharith N; Alabdulkareem K; Alshowair A; Alharbi NK; Alrabiah F; Alshamrani M; Aldibasi O; Alaskar A
    Clin Microbiol Infect; 2022 Apr; 28(4):602-608. PubMed ID: 35026375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Epidemiological Features of SARS-CoV-2 Patients in SARI Ward of a Tertiary Care Centre in New Delhi.
    Aggarwal A; Shrivastava A; Kumar A; Ali A
    J Assoc Physicians India; 2020 Jul; 68(7):19-26. PubMed ID: 32602676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of isolation strategies for asymptomatic and mild symptom COVID-19 patients.
    Suthutvoravut U; Kunakorntham P; Semayai A; Tansawet A; Pattanaprateep O; Piebpien P; Numthavaj P; Thakkinstian A; Atiksawedparit P
    Cost Eff Resour Alloc; 2023 Nov; 21(1):85. PubMed ID: 37946242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.